Press Releases

Month Year

Email Alerts

Jun 24, 2022

BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A

European Commission Approval Expected Q3 2022 1st Gene Therapy for Treatment of Hemophilia A Recommended for Approval in Europe More than 20,000 Adults with Severe Hemophilia A in BioMarin...
Jun 21, 2022

BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed

No Lower Age Restriction for Treatment Japan Accounts for Approximately Half of the 1,500 Patient Opportunity in APAC Region SAN RAFAEL, Calif., June 21, 2022 /PRNewswire/ -- BioMarin...
Jun 13, 2022

BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta

Improvement in Height Z-Score and Annualized Growth Velocity Observed, Consistent with Children Over 5 Interactions with Health Authorities Planned for H2 2022 to Discuss Expanding Access to...
May 31, 2022

BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A

95% Reduction in Mean Annualized Bleed Rate (ABR) and 96% Reduction in Mean Annualized Factor VIII Usage from Baseline Through Year 6 in 6e13 vg/kg Dose Cohort 91% Reduction in Mean ABR and 93%...
May 5, 2022

BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans

Humaira Serajuddin Named to Newly Created Role of Senior Vice President, Chief Marketing Officer Erin Burkhart, Named Group Vice President, Chief Accounting Officer SAN RAFAEL, Calif., May 5, 2022...

Show per page